Although obesity dramatically increases the risk of developing Type
II diabetes, nobody knew why until researchers found a protein that
links the two diseases, opening up the possibility of developing
drugs that prevent diabetes.
The latest in a series of periodic roundups of drugs that have
moved from preclinical research into clinical testing via the
announcement of a Phase I trial or an application for a trial to
Sanofi-Aventis' hotly touted anti-obesity blockbuster drug has
become weighted down in safety concerns as the French company
withdraws its New Drug Application (NDA) in the US and awaits a
safety review in the EU.